Literature DB >> 656270

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

M C Bateson, D Maclean, J R Evans, I A Bouchier.   

Abstract

1 Ten consecutive patients with hypertriglyceridaemia who adhered to a low carbohydrate diet without complete control of serum triglycerides were started on chenodeoxycholic acid 750 mg daily and followed monthly for 6 months. Nine of these patients were then followed for a further month on placebo capsules and thereafter monthly for a further 6 months on clofibrate 2 g daily. 2 The mean serum triglyceride level fell by 36% after dietary treatment alone (P less than 0.05) and by 47% from initial values on diet plus chenodeoxycholic acid (P less than 0.01). In the nine patients who proceeded to clofibrate therapy there was a rise in triglyceride levels on placebo capsules to the level achieved by diet alone, and a further fall on diet plus clofibrate of 47% of initial values (P less than 0.05). 3 Chenodeoxycholic acid therapy is effective in the management of hypertriglyceridaemia not completely cured by dietary measures, and may be as efficacious as clofibrate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656270      PMCID: PMC1429265          DOI: 10.1111/j.1365-2125.1978.tb01632.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA.

Authors:  D S FREDRICKSON; R S LEES
Journal:  Circulation       Date:  1965-03       Impact factor: 29.690

Review 2.  Treatment of hyperlipidemia.

Authors:  R I Levy; J Morganroth; B M Rifkind
Journal:  N Engl J Med       Date:  1974-06-06       Impact factor: 91.245

3.  Serial lipid and lipoprotein responses to the American Heart Association fat-controlled diet.

Authors:  W S Wilson; S B Hulley; M I Burrows; M Z Nichaman
Journal:  Am J Med       Date:  1971-10       Impact factor: 4.965

4.  Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia.

Authors:  N E Miller; P J Nestel
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

5.  Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

Authors:  L A Carlson; L E Böttiger
Journal:  Lancet       Date:  1972-04-22       Impact factor: 79.321

6.  Experience with simplified scheme of treatment of hyperlipidaemia.

Authors:  S Tabaqchali; A Chait; R Harrison; B Lewis
Journal:  Br Med J       Date:  1974-08-10

7.  Clinical evaluation of a new hypolipidemic drug, CIBA 13,437-Su.

Authors:  G Hartmann; G Forster
Journal:  J Atheroscler Res       Date:  1969 Sep-Oct

8.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon; P M McNamara
Journal:  Ann Intern Med       Date:  1971-01       Impact factor: 25.391

9.  Liver structure and function in cholelithiasis: effect of chenodeoxycholic acid.

Authors:  G D Bell; H Y Mok; M Thwe; G M Murphy; K Henry; R H Dowling
Journal:  Gut       Date:  1974-03       Impact factor: 23.059

10.  Potential effect on coronary-heart-disease morbidity of lowering the blood-cholesterol.

Authors:  H M Whyte
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

View more
  19 in total

Review 1.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

2.  Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.

Authors:  Li-Li Shen; Hong Liu; Jiahe Peng; Lin Gan; Li Lu; Qian Zhang; Liangpeng Li; Fengtian He; Yu Jiang
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

Review 3.  Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.

Authors:  Geoffrey Porez; Janne Prawitt; Barbara Gross; Bart Staels
Journal:  J Lipid Res       Date:  2012-05-01       Impact factor: 5.922

4.  The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.

Authors:  Andrea Mencarelli; Sabrina Cipriani; Barbara Renga; Daniela Francisci; Giuseppe Palladino; Eleonora Distrutti; Franco Baldelli; Stefano Fiorucci
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

5.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

6.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 8.  Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

Authors:  J H Iser; A Sali
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

9.  Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model.

Authors:  Ming Kong; Longdong Zhu; Li Bai; Xiaohui Zhang; Yu Chen; Shuang Liu; Sujun Zheng; Stephen J Pandol; Yuan-Ping Han; Zhongping Duan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-09-11       Impact factor: 4.052

Review 10.  Bile acid receptors in non-alcoholic fatty liver disease.

Authors:  Yuanyuan Li; Kavita Jadhav; Yanqiao Zhang
Journal:  Biochem Pharmacol       Date:  2013-08-26       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.